Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Insulin Delivery, Other Sep 19 | 2022Biocorp’s SoloSmart receives CE Mark; EASD 2022 Key Press Releases (Sept 19)Purchase Blast
$599
Posted in: Basal Insulin Sep 19 | 2022Tresiba AG vs. Basal Insulin Pricing AnalysisPurchase Blast
$599
Posted in: Other Sep 15 | 2022Alnylam and Regeneron to Advance NASH ALN-HSD AssetPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Other Sep 13 | 2022Akero Becomes a Frontrunner in NASH; Lilly Initiates Tirzepatide Ph2 TREASURE-CKD Trial; Oramed’s Oral Insulin Ph2 NASH Topline ResultsPurchase Blast
$599
Posted in: Basal Insulin, Other Sep 12 | 2022Novo Partners with Microsoft for Drug Development; Novo Launches Unbranded Degludec; AZ Partners with Gatehouse Bio for HFpEF RNAi Therapeutic Development; September 2022 CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Sep 08 | 2022FENIX Analysis: Mounjaro Launch UpdatePurchase Blast
$599
Posted in: Basal Insulin, Glucagon, Other Sep 08 | 2022Novo Licenses Zealand’s Zegalogue; Adocia Announces Preclinical PoC Data for its Islet Transplant; First Patient Dosed in G&L's QW Insulin Ph1 TrialPurchase Blast
$599
Posted in: Other Sep 06 | 2022Daprodustat FDA Adcom Scheduled for October 26, 2022Purchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Other Sep 02 | 2022Dexcom Promotes Jake Leach to COO; Biocon Receives More Form 483 Observations; Seraxis Appoints Paul Strumph as CMO; Intarcia ITCA-650 CRL Chronicle ConcludesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Sep 01 | 2022Ypsomed Launches Remote Bolus Feature; Lannett Completes Bs-glargine Pivotal Trial; Madrigal Initiates MAESTRO-NASH Outcomes Study for ResmetiromPurchase Blast
$599
Posted in: Other Aug 30 | 2022Repatha CVOT OLE Shows Long-term RRR; Poxel Announces Positive Results for PXL065 Ph2 Trial in NASHPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Other Aug 29 | 2022Thoughts on SURMOUNT-MMO after SELECT Interim AnalysisPurchase Blast
$599
Posted in: Other, SGLT2i Aug 26 | 2022AZ to Initiate Ph2 Dapa + Zibotentan Trial in Cirrhosis; Esperion’s BA Included in ACC's ECDP GuidelinesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, Other Aug 25 | 2022"Mass" Layoff at Beta Bionics?; Novo Initiates Ph3 Ozempic + Lower-Dose Glargine Trial; Novartis to Spin Off Sandoz; Lannett and Adocia CY Q2 ’22 Earnings Updates; Hygieia Appoints New CEOPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Aug 23 | 2022Medtronic CY Q2 ‘22 Earnings Updates; Glytec Collaborates with CPS for Glycemic Management TechnologyPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Aug 22 | 2022Novo Announces Positive Ph2 Cagrisema Results; Insulet’s Omnipod 5 Receives Expanded FDA Clearance; Digbi Health Enrolled in Novo’s Accelerator Program; New Lyumjev Trial for Inreda’s Bi-hormonal AID System; Amarin Discontinues Vazkepa in GermanyPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring Aug 19 | 2022Novo Withdraws PIONEER START Trial; Onduo Partners with Sword Health; Nemaura and Movano Q2 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Insulin Delivery, Other Aug 16 | 2022Sean Saint Takes Over as Beta Bionics CEOPurchase Blast